CPSF1 Double Nickase Plasmid (h): sc-405273-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CPSF1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CPSF1 Double Nickase Plasmid (h) and CPSF1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CPSF1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CPSF1 Antibody (G-10): sc-166281
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CPSF1 Double Nickase Plasmid (h) | sc-405273-NIC | 20 µg | $410.00 |
CPSF1 (cleavage and polyadenylation specificity factor subunit 1) is a core component of the 3′ end pre-mRNA processing machinery that coordinates recognition of polyadenylation signals, endonucleolytic cleavage, and poly(A) tail addition. Through its role in the CPSF complex, CPSF1 couples transcription termination with RNA maturation, shaping transcript stability, nuclear export, and translation efficiency. Perturbation of CPSF1-dependent cleavage and polyadenylation can shift alternative polyadenylation site usage and broadly remodel gene expression programs linked to cell cycle control, differentiation, and stress responses. Dysregulated mRNA 3′ end processing has been associated with proliferative and neurodevelopmental phenotypes, making CPSF1 a useful node for studying RNA processing–driven disease mechanisms in human cells.
CPSF1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CPSF1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CPSF1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CPSF1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CPSF1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.